MHC tetramer detailed product information

Code No. TS-M014-1
T-Select HLA-A*24:02 modified WT1 Tetramer-CYTWNQMNL-PE
Price ¥209,000
Size 50 tests
Availability (in Japan) 0
(Contact us)
（In Japan at 17:00, Apr 19, 2024 in JST）
Class Class I
Animal species Human
Category cancer
Conjugate PE
Immunogen (Antigen) modified WT1
Sequence CYTWNQMNL
MHC Allele A*24:02
Location (aa) 235-243
Storage temp. 4°C
Manufacturer MBL
Related products TS-M140-1 HLA-A*02:01 WT137-45 Tetramer-VLDFAPPGA-PE
TS-M140-2 HLA-A*02:01 WT137-45 Tetramer-VLDFAPPGA-APC
Product category Research area:Immunology
Tools:MHC tetramer
Citations
  1. Saitoh A et al. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med Oncol. 28, 219-230 (2011)(PMID:20107936)
  1. Chiba Y et al. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol. 40, 395-403 (2010)(PMID:20364021)
  1. Narita M et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci. 7, 72-81 (2010)(PMID:20428337)
  1. Tsuboi A et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 86, 414-417 (2007)(PMID:18192109)
  1. Najima Y et al. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 127,722-34(2016)(PMID:26702062)
  1. Nishida S et al. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunol Res. (2018) In press.(PMID:29358173)
  1. Yanagisawa R et al. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Anticancer Res. 38, 2217-2225 (2018)(PMID:29599342)
  1. Matsuda T et al. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncol Lett. 16, 1348-1356 (2018)(PMID:29963201)
  1. Watanabe K et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 110, 40-51 (2019)(PMID:30375705)
  1. Morimoto S et al. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget 9, 34132-34141 (2018)(PMID:30344927)
  1. Zhang W et al. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother.68, 121-130 (2019)(PMID:30306202)
  1. Tsuboi A et al. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 68, 331-340 (2019)(PMID:30430205)
  1. Nishida S et al. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments. Medicine (Baltimore) 98, e16771 (2019)(PMID:31415377)
  1. Nagai K et al. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial. Anticancer Res. 40, 5765-5776 (2020)(PMID:32988904)
  • The availability is based on the information in Japan at 17:00, Apr 19, 2024 in JST.
  • The special price is shown in red color.
  • Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
  • For storage temparature: RT: room temparature
  • Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.
MBLCopyright (C)2015 Medical ＆ Biological Laboratories Co., Ltd. All Rights Reserve